Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 18/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 13/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 12/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056008 | 0.91 | PDE10A (0.54) | PDE10APDE3APDE3B | |
| SCHEMBL3051634 | 0.88 | PDE10A (0.54) | PDE10APDE3APDE3BPDE4APDE4B | |
| SCHEMBL3051849 | 0.88 | PDE10A (0.52) | PDE10APDE3APDE3B | |
| SCHEMBL3051678 | 0.86 | PDE10A (0.48) | PDE10APDE3APDE3B | |
| SCHEMBL3051960 | 0.86 | PDE10A (0.51) | PDE10APDE3APDE3B | |
| SCHEMBL3056507 | 0.85 | PDE10A (0.48) | PDE10APDE3APDE3B | |
| SCHEMBL3052625 | 0.84 | PDE10A (0.52) | PDE10APDE3APDE3B | |
| SCHEMBL3059880 | 0.83 | PDE10A (0.57) | PDE10APDE3APDE3B | |
| SCHEMBL3052396 | 0.82 | PDE10A (0.70) | PDE10APDE3A | |
| SCHEMBL3057869 | 0.81 | PDE10A (0.57) | PDE10APDE3APDE3BPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | claimed |
| EP-1981868-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | Pfizer Products Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007085954-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1981868-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | Pfizer Products Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085954-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PDE12, PDE5A, PDE2A | PDE10A 6/4885PDE3A 5/4885PDE3B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.